| Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer (NCT04171622) | M.D. Anderson Cancer Center | 2021-11-04 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer (NCT04759911) | M.D. Anderson Cancer Center | 2021-02-26 |
| Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer (NCT04731740) | Saint Petersburg State University, Russia | 2020-12-28 |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer (NCT04544111) | Memorial Sloan Kettering Cancer Center | 2020-09-02 |
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (NCT03914300) | National Cancer Institute (NCI) | 2020-02-10 |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer (NCT03630120) | H. Lee Moffitt Cancer Center and Research Institute | 2018-08-06 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (NCT03449108) | M.D. Anderson Cancer Center | 2018-04-27 |
| Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (NCT02973997) | Academic and Community Cancer Research United | 2018-02-07 |
| Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer (NCT03181100) | M.D. Anderson Cancer Center | 2017-07-27 |
| Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer (NCT02393690) | Academic and Community Cancer Research United | 2015-05-04 |
| Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (NCT02152995) | National Cancer Institute (NCI) | 2014-08-14 |
| Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (NCT01811212) | National Cancer Institute (NCI) | 2013-05-08 |